245 results on '"Kuo, Yuan-Yeh"'
Search Results
2. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations
3. Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends
4. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
5. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
6. Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis
7. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
8. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
9. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
10. Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/Neoplasms
11. IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.
12. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
13. Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification
14. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
15. P721: VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION
16. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia
17. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms
18. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis
19. Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification
20. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia
21. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
22. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome
23. Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratification
24. Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
25. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients
26. AML-765 Refinement of Myelodysplasia-Related Gene Mutations Listed in the 2022 European LeukemiaNet (ELN-2022) Guidelines Enhances Prognostic Stratification in Acute Myeloid Leukemia
27. Refinement of Myelodysplasia-Related Gene Mutations Listed in the 2022 European LeukemiaNet (ELN-2022) Guidelines Enhances Prognostic Stratification in Acute Myeloid Leukemia
28. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
29. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution
30. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications
31. Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia
32. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
33. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
34. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
35. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients
36. SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
37. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
38. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
39. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
40. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer
41. GATA-1 mediates auto-regulation of Gfi-1B transcription in K562 cells
42. GATA-1 and NF-Y cooperate to mediate erythroid-specific transcription of Gfi-1B gene
43. The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia
44. Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy
45. Discrepant Mutational Composition between Myeloid Sarcoma and Bone Marrow Leukemia Revealed through Targeted Next Generation Sequencing
46. Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3-ITD Patients
47. Botanical Alkyl Hydroquinone Derivative HQ17(3) Induces Calcium-Associated Mitochondrial Damage and Mitophagy to Exert Ctotoxicity to Philadelphila Chromosome(+) ALL Cells
48. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor inde novoacute myeloid leukemia patients
49. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
50. Incorporation of Long Non-Coding RNA Expression Profile in the 2017 ELN Risk Classification Can Improve Prognostic Prediction of Acute Myeloid Leukemia Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.